Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005954
Abstract: Key Points Glofitamab induced dose-dependent induction of cytokines and T-cell margination, proliferation, and activation in peripheral blood. Tumor cell intrinsic factors (eg, TP53 and MYC signaling) are associated with resistance to glofitamab. read more here.
Keywords: pharmacodynamics molecular; molecular correlates; correlates response; glofitamab ... See more keywords
Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.7519
Abstract: 7519 Background: Glofitamab (RG6026), a T-cell-engaging, bispecific, full-length antibody, allows bivalent binding to CD20 (B-cells), and monovalent binding to CD3 (T-cells). In NP30179 (NCT03075696), an ongoing multicenter, Phase I dose-escalation and expansion study, 0.6–25mg glofitamab… read more here.
Keywords: response; response rates; efficacy; updated efficacy ... See more keywords